Does REZDIFFRA Lower LDL Levels?
Yes, resmetirom (REZDIFFRA) significantly lowers LDL cholesterol levels by approximately 14–20% in patients with NASH and moderate to advanced fibrosis. 1
Magnitude of LDL-C Reduction
In patients with elevated baseline LDL cholesterol, resmetirom 80 mg reduced LDL-C by 14% and the 100 mg dose reduced it by 20% after 52 weeks of treatment, compared to 0% change in the placebo group. 1
At 24 weeks, the LDL-C reduction from baseline was -13.6% with the 80 mg dose and -16.3% with the 100 mg dose, versus 0.1% with placebo (P<0.001 for both comparisons). 2
In the MAESTRO-NAFLD-1 safety trial, resmetirom achieved LDL-C reductions of -11.1% (80 mg) and -12.6% (100 mg) compared to placebo at 24 weeks. 3
Additional Lipid Benefits Beyond LDL-C
Apolipoprotein B decreased by 23.8% (P<0.0001) and triglycerides fell by 19.6% (P=0.0012) in the extension study, demonstrating comprehensive lipid-lowering effects. 4
In the phase 3 MAESTRO-NAFLD-1 trial, apoB decreased by -15.6% (80 mg) and -18.0% (100 mg), while triglycerides fell by -15.4% (80 mg) and -20.4% (100 mg) compared to placebo (P<0.0001 for all). 3
Clinical Implications for Statin Co-Administration
Because resmetirom provides significant LDL-C lowering, the FDA-mandated statin dose reductions (rosuvastatin and simvastatin limited to ≤20 mg/day; pravastatin and atorvastatin limited to ≤40 mg/day) are not expected to negatively impact cardiovascular risk management. 1
In the phase 3 trials supporting FDA approval, approximately half of patients were on concomitant statins at baseline, and this subpopulation demonstrated similar efficacy and safety profiles compared to those not taking statins. 1
Clinicians should continue to adhere to LDL-C targets in patients at high cardiovascular risk and adjust statin dosing or use other lipid-lowering agents as appropriate, recognizing that resmetirom's lipid benefits may compensate for required statin dose reductions. 1
Mechanism of Lipid Lowering
Resmetirom is a selective thyroid hormone receptor-beta agonist that acts primarily in the liver to enhance mitochondrial oxidation and lipophagy, thereby reducing hepatic fat content and improving lipid metabolism. 5
The drug increases plasma concentrations of some statins through CYP2C8 and OATP1B1/1B3 interactions, which theoretically could increase statin-related adverse events, though none were observed in clinical trials. 1